Vanesa G.
- Country
- Italy
- Department
- Medical Oncology Department
Research Overview
- Dose-Escalation Study of Zongertinib in Patients with Advanced Non-Small Cell Lung Cancer and Solid Tumors with HER2 Aberrations
- Phase 1 Evaluation of BL-B01D1 Safety, Tolerability, and Efficacy in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
Data & Insights
Has run more than one trial at 473 of 810 partner sites.
Specializations
Breast Cancer Research
Specializes in investigating novel therapeutic approaches for hormone receptor-positive and HER2-positive breast cancer. Focuses on evaluating targeted therapies and combination treatments for both early-stage and metastatic disease.
- Advanced metastatic breast cancer
- Early-stage breast cancer treatment
- Hormone receptor-positive disease
Lung Cancer Studies
Conducts research in non-small cell lung cancer treatment strategies, with particular emphasis on targeted therapies for specific mutations including KRAS G12C and HER2 mutations.
- Advanced NSCLC therapies
- Mutation-specific treatments
- Immunotherapy combinations
Gynecologic Oncology
Investigates treatments for ovarian cancer, endometrial cancer, and cervical cancer. Specializes in maintenance therapies and novel combination approaches for advanced disease.
- Advanced ovarian cancer
- Endometrial cancer treatments
- Cervical cancer therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.